Gene therapy breakthrough: could a single infusion free thalassemia patients from lifelong transfusions?

NCT ID NCT05577312

First seen Jan 18, 2026 · Last updated May 10, 2026 · Updated 19 times

Summary

This study tests a one-time gene therapy called BRL-101 for people with transfusion-dependent β-thalassemia, a severe blood disorder requiring regular transfusions. The therapy uses the patient's own blood stem cells, modified with CRISPR-Cas9, to help the body produce healthy red blood cells. The goal is to see if a single infusion can safely reduce or eliminate the need for transfusions. The trial involves 39 participants aged 3 to 35.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, 510510, China

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, 530021, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, 510510, China

Conditions

Explore the condition pages connected to this study.